ES2556468T3 - Mutaciones en el gen del receptor del factor de crecimiento epidérmico - Google Patents

Mutaciones en el gen del receptor del factor de crecimiento epidérmico Download PDF

Info

Publication number
ES2556468T3
ES2556468T3 ES12745460.1T ES12745460T ES2556468T3 ES 2556468 T3 ES2556468 T3 ES 2556468T3 ES 12745460 T ES12745460 T ES 12745460T ES 2556468 T3 ES2556468 T3 ES 2556468T3
Authority
ES
Spain
Prior art keywords
egfr
cetuximab
mutant
cells
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12745460.1T
Other languages
English (en)
Spanish (es)
Inventor
Clara Montagut Viladot
Joan Albanell Mestres
Ana Rovira Guerin
Beatriz Bellosillo Paricio
Alba Dalmases Massegú
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Original Assignee
Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut Hospital del Mar d'Investigacions Mèdiques filed Critical Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Application granted granted Critical
Publication of ES2556468T3 publication Critical patent/ES2556468T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES12745460.1T 2011-08-03 2012-08-02 Mutaciones en el gen del receptor del factor de crecimiento epidérmico Active ES2556468T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (en) 2011-08-03 2011-08-03 Mutations in the epidermal growth factor receptor gene
EP11382270 2011-08-03
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
ES2556468T3 true ES2556468T3 (es) 2016-01-18

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12745460.1T Active ES2556468T3 (es) 2011-08-03 2012-08-02 Mutaciones en el gen del receptor del factor de crecimiento epidérmico

Country Status (12)

Country Link
US (1) US9765399B2 (cg-RX-API-DMAC7.html)
EP (3) EP2554551A1 (cg-RX-API-DMAC7.html)
JP (1) JP6149034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140072035A (cg-RX-API-DMAC7.html)
CN (1) CN103717616B (cg-RX-API-DMAC7.html)
AU (1) AU2012292024A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002373A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842270C (cg-RX-API-DMAC7.html)
ES (1) ES2556468T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN00570A (cg-RX-API-DMAC7.html)
RU (1) RU2014107908A (cg-RX-API-DMAC7.html)
WO (1) WO2013017645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
JP6905464B2 (ja) * 2014-07-28 2021-07-21 フンダシオ インスティトゥ マー ディンヴェスティガシオンズ メディクー(イーエメイーエメ) 上皮増殖因子受容体遺伝子の細胞外ドメインiii内の変異
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
EP3286219A1 (en) * 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558753A1 (en) 2004-03-01 2005-09-15 University Of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2601936C (en) * 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
JP5596975B2 (ja) * 2006-10-26 2014-10-01 ジェネンテック, インコーポレイテッド 腫瘍と関連している遺伝的変異
CA2675362A1 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options

Also Published As

Publication number Publication date
BR112014002373A2 (pt) 2017-02-21
CA2842270A1 (en) 2013-02-07
RU2014107908A (ru) 2015-09-10
EP2554551A1 (en) 2013-02-06
AU2012292024A1 (en) 2014-02-27
WO2013017645A1 (en) 2013-02-07
JP2014521342A (ja) 2014-08-28
KR20140072035A (ko) 2014-06-12
EP2739648A1 (en) 2014-06-11
US9765399B2 (en) 2017-09-19
US20140170662A1 (en) 2014-06-19
CN103717616A (zh) 2014-04-09
JP6149034B2 (ja) 2017-06-14
EP2739648B1 (en) 2015-09-16
CN103717616B (zh) 2016-06-29
EP2995623A1 (en) 2016-03-16
CA2842270C (en) 2019-10-29
IN2014CN00570A (cg-RX-API-DMAC7.html) 2015-04-03

Similar Documents

Publication Publication Date Title
ES2663556T3 (es) Anticuerpos frente al receptor alfa del folato y usos de los mismos
ES2661238T3 (es) Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer
ES2687783T3 (es) Biomarcadores de cáncer y usos de los mismos
ES2540802T3 (es) Proteínas de unión específica y uso de las mismas
ES2753360T3 (es) Anticuerpos contra PD-L1 y usos de los mismos
ES2833962T3 (es) Respuesta antitumoral a epítopos propios modificados
US20160245812A1 (en) Tumor cell-derived microvesicles
ES2894323T3 (es) Sistema y productos para una mejor cuantificación de la actividad ADCC
JP7279026B2 (ja) Napi2b標的化療法に対する応答を予測するための組成物および方法
ES2523992T3 (es) La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
HRP20100412T1 (hr) Identifikacija površinskih antigena radi dijagnoze i liječenja tumora
Hasegawa et al. Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor
ES2901602T3 (es) Composiciones y métodos para detectar y tratar el cáncer ovárico
JPWO2019065747A1 (ja) 抗ckap4モノクローナル抗体
Kim et al. Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2)
JP2017526916A (ja) 癌の診断
Rathore et al. Liver endothelium microenvironment promotes HER3-mediated cell growth in pancreatic ductal adenocarcinoma
Hu et al. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis
ES2382987T3 (es) Método de detección de cáncer de hígado, diagnóstico de cáncer de hígado y curación del cáncer
Mizuguchi et al. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia
Nelson et al. An increasingly important therapeutic target: Part 2 Distribution of HER2/neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology
ES2857606T3 (es) Isoformas delta133P53beta y delta133P53gamma son biomarcadores de células madre cancerosas
Geng et al. S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K/Akt/mTOR pathway
Klotz et al. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474
ES2693080T3 (es) Mutaciones en el dominio extracelular III del gen del receptor del factor de crecimiento epidérmico